Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
Kyu Yong Cho (Cho KY), Akinobu Nakamura (Nakamura A), Chiho Oba-Yamamoto (Oba-Yamamoto C), Kazuhisa Tsuchida (Tsuchida K), Shingo Yanagiya (Yanagiya S), Naoki Manda (Manda N), Yoshio Kurihara (Kurihara Y), Shin Aoki (Aoki S), Tatsuya Atsumi (Atsumi T), Hideaki Miyoshi (Miyoshi H)
Diabetes Metab J. 2020;44(4):532-541.   Published online 2019 Nov 22     DOI: https://doi.org/10.4093/dmj.2019.0093
Citations to this article as recorded by Crossref logo
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
Tevfik Demir, Serap Turan, Kursad Unluhizarci, Oya Topaloglu, Tufan Tukek, Dilek Gogas Yavuz
Frontiers in Endocrinology.2021;[Epub]     CrossRef
Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
Anwar Ali Jammah
Primary Care Diabetes.2020;[Epub]     CrossRef
Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
I. N. Dyakov, S. K. Zyryanov
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.2020; : 4.     CrossRef